Recent Updates
Recently added Catalysts

GSI 136

Phase 1

Alzheimer Disease | Small molecule | Neurology |Pfizer, Inc.|Last Updated: Apr 2, 2010

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials2
Total Enrollment152
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00718731Study GSI-136 in Healthy Young and Healthy Elderly SubjectsPHASE1 COMPLETED 80Mar 1, 2008Aug 1, 2008Apr 2, 20101 United States
NCT00719394Study Evaluating Safety of GSI 136 in Young and Elderly Japanese MalesPHASE1 COMPLETED 72Mar 1, 2008Aug 1, 2008Jul 10, 20091 Japan
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Safety and tolerability of GSI-136 as evaluated from reported adverse events, scheduled physical examinations, vital sign measurements, orthostatic vital sign measurements, cardiac rhythm monitoring, 12-lead ECGs, and clinical laboratory test results.
6 months
Secondary Endpoints
Pharmacokinetics as evaluated from the blood and urine concentrations of GSI-136; Pharmacodynamics as evaluated from the levels of select biomarkers in the blood and the administration of a visual analog scale to measure sedation effects.
6 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
1EXPERIMENTALSubject on active drug
2PLACEBO_COMPARATORSubject on placebo
GSI 136EXPERIMENTAL -
placeboPLACEBO_COMPARATOR -
Interventions
NameTypeDescription
GSI-136DRUG -
PlaceboOTHER -
GSI 136DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersYes
Study Sites1

\<Inclusion: 1. Men or women of nonchildbearing potential (WONCBP) aged 18 to 50 years or greater than 65 years, inclusive, at screening. WONCBP may be included if they are either surgically sterile (hysterectomy and/or oophorectomy) or postmenopausal for greater than 1 year (with follicle-stimulat...

Countries:United StatesJapan
Unlock Eligibility Criteria